Bayer Statement on Defense Verdict in Gordon
Bayer today issued the following statement on the defense verdict in the Gordon trial.
Bayer today issued the following statement on the defense verdict in the Gordon trial.
Bayer today issued the following statement on the filing of the company’s en banc brief in the Eleventh Circuit Court of Appeals in Carson.
Bayer today issued the following statement on the Eleventh Circuit order granting the Company’s petition for rehearing en banc in Carson.
Bayer today issued the following statement on the defense verdict in the Ferro case.
Bayer today issued the following statement on the verdict in the Alesi case.
Bayer today issued the following statement on the Eleventh Circuit’s decision in the Carson case.
Bayer today issued the following statement on the Supreme Court’s decision to deny review of the Pilliod case.
Bayer today issued the following statement on the Supreme Court’s decision to deny review of the Hardeman case.
Bayer today issued the following statement on the full defense verdict issued in the Johnson trial.
Bayer today issued the following statement on the full defense verdict issued in the Shelton trial.
Bayer today provided an update on its five-point plan to address future Roundup™ litigation risk after its May 27th decision to withdraw from the national class process. The company is now in more control of important aspects of the risk mitigation process and has sketched out two basic scenarios going forward to provide a path to closure of this litigation. The first scenario is based on obtaining a favorable decision by the United States Supreme Court on a cross-cutting issue like federal preemption which would effectively and largely end the U.S. Roundup™ litigation. The second scenario assumes that the Supreme Court either declines to hear the Hardeman case or issues a ruling in favor of plaintiff – in that case the company would activate its own claims administration program.
Read about the five-point plan here.